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Abstract 
 
Specific differentiation of bone marrow-derived mesenchymal stem 
cells by regulation of protein kinase system 
 
Woochul Chang 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Yangsoo Jang) 
 
Protein kinases, the members of a large family of proteins involved in 
modulating many known signaling pathways, are likely to play important roles 
in regulating stem cell differentiation programs because important bio-processes 
such as cell fate are likely to be determined by an elaborate orchestration of 
multiple signaling pathways. In addition, cell permeable small molecules to 
modulate activation of protein kinase have several merits that include the ability 
for temporal, tunable and modular control of specific protein function. 
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Therefore, research efforts focused on search for chemical reagent and 
mechanism that regulates systematic differentiation of MSCs. It was found that 
some of protein kinase cause recognizable changes in differentiation rates of 
MSCs based on screening inhibitors of major protein kinase subfamilies to alter 
the orchestration of multiple signaling pathways. At first, chondrogenesis of 
MSCs in vitro was significantly improved in cells treated with H-89, a PKA 
inhibitor. After treatment of H-89, the data of alcian blue staining assay for the 
quantitation of chondrogenesis was increased. Aggrecan, one of the 
extracellular matrix genes in chondrocytes, was induced in MSCs treated with 
various concentrations of H-89 (0.1–1 µM). During chondrogenesis of MSC, 
activation of ERKs was increased in MSCs treated with H-89 but cotreatment 
with H-89 and U0126 did not lead to a change in ERK activation. 
Semiquantitative RT-PCR showed a significantly changed level of cell adhesion 
molecule during chondrogenesis. MSCs gave rise to cardiomyocytes expressing 
of cardiac-specific markers (cardiac troponin T, myosin light chain, myosin 
heavy chain, NK2 transcription factor-related, locus 5, and Myocyte-specific 
enhancer factor 2) by addition of phorbol myristate acetate (PMA), a PKC 
activator. Differentiated cardiomyocytes expressed functional adrenergic and 
muscarinic receptors and norepinephrine induced phosphorylation of ERK via 
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α1-adrenoceptors. The mRNA level of Ca2+-related factor (sarcoplasmic 
reticulum Ca2+-ATPase, L-type Ca2+ channel) in differentiated MSCs was 
similar to that in cardiomyocytes. Differentiation into endothelial-like cells was 
induced by cultivation of cells in the presence of GSK-3β inhibitor. The 
differentiated cells showed a strong increase of expression of 
endothelial-specific markers (CD31, CD34, eNOS, VE-cadherin, VCAM-1, and 
VEGF-R2) and functional behavior of endothelial cells such as a formation of 
capillary-like structure. Treatment of proliferating MSCs with GSK-3β inhibitor 
leads to depletion of S-phase cells and over all decreased proliferation. The 
differentiation of MSCs into endothelial-like cells by the treatment of GSK-3β 
inhibitor was associated with GSK-3β/β-catenin signaling. The current study 
suggests that the regulation of protein kinase may emerge as a remarkable tool 
for systematic differentiation of MSCs. This system would greatly contribute to 
a novel understanding of MSC biology and the development of novel 
regenerative medicine. 
 
---------------------------------------------------------------------------------------------------------- 
Key words: Mesenchymal stem cell, Differentiation, Protein kinase, Signaling 
pathway 
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I. INTRODUCTION 
A stem cell is an extraordinary type of cell that has the ability to self-renew for 
long periods of time and to differentiate into specialized cells under appropriate 
physiological or experimental conditions 1. Traditionally, stem cells are 
classified as either embryonic or adult (tissue-specific) stem cells. Embryonic 
stem cells (ESCs) are derived from the inner cell mass of the blastocyst stage 
embryo. They possess an unlimited capacity for self-renewal and have the 
potential to develop into any cell type found in the three primary germ layers of 
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the embryo (endoderm, mesoderm and ectoderm), as well as germ cells and 
extraembryonic cells 2-4. In contrast, adult stem cells are found in differentiated 
tissues, have limited self-renewal capability, and generally can only 
differentiate into specialized (mature) cell types of the tissue in which they 
reside.  
It may be that adult stem cells in adult tissues are reservoirs of reparative cells, 
ready to mobilize and differentiate in response to wound signals or disease 
conditions. Little information is currently available about the biology of 
endogenous stem cell populations in adults and their precise role in tissue repair 
or regeneration. This may be due in part to the lack of useful cell-specific 
markers. What is clear, however, is the ease with which these cells can be 
isolated and expanded in culture through many generations while retaining the 
capacity to differentiate. Recent progress in the isolation and characterization of 
these cells has led to the development and testing of therapeutic strategies in a 
variety of clinical applications. 
Mesenchymal stem cells (MSCs), which reside within the stromal compartment 
of bone marrow were first identified in the pioneering studies of Friedenstein 
and Petrakova, who isolated bone-forming progenitor cells from rat marrow 5. 
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They play a role in providing the stromal support system for haematopoietic 
stem cells in the marrow. In addition, they have the capacity to differentiate into 
cells of connective tissue lineages, including bone, fat, cartilage and muscle. 
The multilineage differentiation potential of MSC populations derived from a 
variety of different species has been extensively studied in vitro since their first 
discovery in 1960s 5. These studies demonstrate that populations of bone 
marrow derived MSCs from human, canine, rabbit, rat, and mouse have the 
capacity to develop into terminally differentiated mesenchymal phenotypes both 
in vitro and in vivo, including bone, cartilage, tendon, muscle, adipose tissue, 
and hematopoietic-supporting stroma 6-13. In that, MSCs are considered a 
readily accepted source of stem cells because such cells have already 
demonstrated efficacy in multiple types of cellular therapeutic strategies, 
including applications in treating children with osteogenesis imperfecta, 
hematopoietic recovery, and bone tissue regeneration strategies 14-17. MSCs 
represent a very small fraction, 0.001–0.01% of the total population of 
nucleated cells in marrow. However, they can be isolated and expanded with 
high efficiency. More importantly, these cells may be directly obtained from 
individual patients, thereby eliminating the complications associated with 
immune rejection of allogenic tissue.  
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As state above, an important feature about MSCs is their multilineage 
differentiation potential. Under defined inductive conditions, MSCs are able to 
acquire characteristics of cells derived from embryonic mesoderm, such as 
osteoblasts, chondrocytes, adipocytes, tendon cells, as well as cells possessing 
ectodermal and neuronal properties. Based on the genetic and genomic 
information provided by various studies, MSCs undergo transcriptional 
modification, generating precursor cells without apparent changes in phenotype 
and self-renewal capacity. Similar to MSCs residing in adult bone marrow, the 
majority of MSCs cultured in vitro remain quiescent and growth arrested in 
G0/G1, until stimulated, for example, by the supplementation of growth factors. 
Upon stimulation, multipotent, uncommitted MSCs undergo asymmetric 
division, giving rise to two daughter cells, one being the exact replica of the 
mother cell and maintaining multilineage potential, and the other daughter cell 
becoming a precursor cell, with a more restricted developmental program. In 
this, the precursor cell continues to divide symmetrically, generating more 
tripotent and bipotent precursor cells. These tripotent and bipotent precursor 
cells are morphologically similar to the multipotent MSCs, but differ in their 
gene transcription repertoire, and therefore, still reside in the stem cell 
compartment. The progression of MSCs to precursor cells is considered the first 
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step in stem cell commitment. The transition or exit from the ‘stem cell 
compartment’ to the ‘commitment compartment’ occurs when precursor cells 
continue to divide symmetrically to generate unipotent progenitor cells, 
simultaneous with the acquisition of lineage specific properties, rendering them 
fully committed mature cells with distinguishable phenotypes.  
Despite diverse and growing information concerning MSCs and their use in 
cell-based strategies, the mechanisms that govern MSC self-renewal and 
multilineage differentiation are not well understood and remain an active area of 
investigation. Especially, what is not fully understood is the mechanism that 
governs the transit of uncommitted stem cells to partially committed precursor 
or progenitor cells, and then to fully differentiated cells. Therefore, research 
efforts focused on identifying factors that regulate and control MSC cell fate 
decisions are crucial to promote a greater understanding of the molecular, 
biological and physiological characteristics of this potentially highly useful 
stem cell type. 
Stem cell fate is determined by both intrinsic regulators and the extra-cellular 
environment (niche), and their expansion and differentiation ex vivo are 
generally controlled by growing them in a specific configuration (monolayer or 
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three dimensional culture) with ‘‘cocktails’’ of growth factors and signaling 
molecules, as well as genetic manipulations 18-22. However, most of these 
conditions are either incompletely defined, or non-specific in regulating the 
desired cellular process. As a consequence, more efficient and selective 
methods to control the fate of stem cells to produce homogenous populations of 
particular cell types will be essential to the therapeutic use of stem cells and will 
facilitate studies of the molecular mechanisms of development. In this study, we 
hypothesize that pathway specific screens of synthetic small molecules to effect 
protein kinases system will provide useful chemical tools to modulate and study 
complex cellular processes because protein kinases play a critical role in many 
signaling pathways such as development, differentiation, proliferation or death 
not also undefined media often result in inconsistency in cell culture and/or 
heterogeneous populations of cells which would not be useful for cell-based 
therapy and would complicate the biological study of a particular cellular 
process.  
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II. MATERIALS AND METHODS 
1. Isolation and culture of MSCs 
MSCs were isolated from the femoral and tibial bones of rats. Bone 
marrow-derived MSCs were collected from the aspirates of the femurs and 
tibias of 4-week-old male Sprague-Dawley rats (approximately 100 g) with 10 
ml of MSC medium consisting of Dulbecco’s modified Eagle’s medium 
(DMEM)-low glucose, supplemented with 10% fetal bovine serum and 1% 
antibiotic-penicillin and streptomycin solution. Mononuclear cells recovered 
from the interface after centrifugation in Percoll were washed twice, 
resuspended in 10% fetal bovine serum (FBS)-DMEM, and plated in flasks at 
1×106 cells per 100 cm2. Cultures were maintained at 37°C in a humidified 
atmosphere containing 5% CO2. After 48 or 72 hrs, nonadherent cells were 
discarded, and the adherent cells were thoroughly washed twice with 
phosphate-buffered saline (PBS). Fresh complete medium was added and 
replaced every 3 or 4 days for approximately 10 days. To further purify the 
MSCs, the Isolex Magnetic Cell Selection System (Baxter Healthcare 
Corporation, Irvine, CA, USA) was used. Briefly, cells were incubated with 
Dynabeads M-450 coated with anti-CD34 monoclonal antibody. A magnetic 
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field was applied to the chamber and the CD34+ cell-bead complexes were 
separated magnetically from the remaining cell suspension with the 
CD34-negative fraction being further cultured. The cells were harvested after 
incubation with 0.25% trypsin and 1 mM EDTA for 5 min at 37°C, replated in 
1×105/100-cm2 plates, and again grown for approximately 10 days.  
 
2. MSCs characterization 
Immunocytochemical characterization of MSCs was demonstrated below. Cells 
were cultured in 4 well side chamber, washed with PBS and incubated 1 % 
paraformaldehyde solution (Sigma, St. Louis, MO, USA) for 10 minutes. PBS 
washing twice, then cells has permeated in 0.1 % Triton X-100 for 7 minutes. 
After PBS washing twice, they have blocked for 1 hours (blocking solution: 
2 % bovine serum albumin, 10 % horse serum in PBS) and adhered with the 
following antibodies: CD34, CD71, CD90, CD105, and intracellular adhesion 
molecule (ICAM)-1. FITC-conjugated mouse, rabbit and goat (Jackson 
Immunoresearch Laboratories, West Grove, PA, USA) were used as secondary 
antibodies. Then, they were detected confocal microscopy (Carl Zeiss, 
Thornwood, NY, USA). MSCs were performed according to the procedure of 
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fluorescence-activated cell sorting (FACS) staining described below. Briefly, 
cells were detached from the plate with 10 % trypsin-EDTA (Gibco BRL, Grand 
Island, NY, USA), washed in PBS and fixed in 70 % ethanol at 4 °C for 30 
minutes with agitation. Cells were washed twice in PBS and resuspended at 
2×106 cells/ml in blocking buffer (1 % BSA, 0.1 % FBS) containing the 
following antibodies: CD14, CD34, CD90, CD 105, ICAM-1 ; In the case of 
CD14, we used normal rabbit IgG as a negative isotype control. After staining, 
cells were washed twice and then labeled with rabbit or mouse-FITC conjugated 
IgG for 20 minutes in the dark area. After two more washes, flow cytometric 
analysis was performed on a FACS Calibur system (Becton Dickinson, Franklin 
Lakes NJ, USA) using CellQuest™ software (Becton Dickinson, Franklin 
Lakes NJ, USA) with 10,000 events recorded for each sample. 
 
3. Screening of protein kinase inhibitors for differentiation of MSCs 
We assembled a small library of commercially available chemicals. Of these, a 
subset of compounds was selected based on their low cytotoxicity. These 
compounds were screened for their activity to differentiate MSCs. 
 
 13 
4. Alcian Blue staining 
Cells were first rinsed with PBS (Gibco BRL, Grand Island, NY, USA) three 
times then fixed with 100% methanol (Sigma, St. Louis, MO, USA) for 10 min 
at -20°C. Staining was accomplished by applying a solution of 1% Alcian blue 
8GX (Bio Basic, Ontario, Canada) in 0.1 M HCl (pH 1.0) (Sigma, St. Louis, 
MO, USA) to the cells for 2hr at room temperature. To quantify the intensity of 
the staining, the stained culture plates were rinsed with PBS three times and 
each well was extracted with 1 ml of 6M guanidine-HCl (Sigma, St. Louis, MO, 
USA) overnight at room temperature. The optical density of extracted dye was 
measured at 650nm. 
 
5. Sandwich ELISA 
The capture antibody was bound to the bottom of each well and then the plate 
was incubated overnight at 4℃. The plate was washed twice with PBS (Gibco 
BRL, Grand Island, NY, USA) and treated with 100 µl of 3% BSA (Sigma, St. 
Louis, MO, USA) /PBS for 2~3 hrs at 37℃ at room temperature. After washing 
the plate twice with PBS, cell lysate was added to each well and the plate was 
incubated for at least 2 hrs at room temperature in a humid atmosphere. The 
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plate was washed four times with PBS containing 0.02% tween-20 (Sigma, St. 
Louis, MO, USA). Following adding the detector antibody, the plate was 
incubated for 2 hrs at room temperature in a humid atmosphere. The plate was 
incubated again with addition of peroxidase conjugated secondary Ab for 1 hr at 
37°C. Finally, the plate was treated with 100 µl of TMB (tetramethylbenzidine, 
Sigma, St. Louis, MO, USA) as substrate and 25 µl of 0.1 M H2SO4 as stop 
buffer, then detected immediately at 450nm on an ELISA plate reader. 
 
6. Immunocytochemistry 
Cells were grown on 4-well plastic dishes (SonicSeal Slide, Nalge Nunc, 
Rochester, NY, USA). Following incubation, cells were washed twice with PBS 
and then fixed with 4% paraformaldehyde in 0.5 ml PBS for 30 min at room 
temperature. The cells were washed again with PBS and then permeabilized for 
30 min in PBS containing 0.2% triton. The cells were then blocked in PBS 
containing 10% goat serum and incubated for 1 hr with primary antibody. The 
cells were rewashed three times for 10 min with PBS and incubated with 
FITC-conjugated secondary antibody for 1 hr. Photographs of cells were taken 
under fluorescence by immunofluorescence microscopy (Olympus, Melville, 
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NY, USA). All images were made by using an excitation filter under reflected 
light fluorescence microscopy and transferred to a computer equipped with 
MetaMorph software ver. 4.6 (Universal Imaging Corporation Ltd., Marlow, 
UK). 
 
7. Immunoblot analysis 
Cells were washed once in PBS and lysed in a lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA) containing 20 mM Tris (pH 7.5), 150 mM 
NaCl, 1 mM Na2-EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin, 
and 1 mM phenylmethylsulfonyl fluoride. Protein concentrations were 
determined using the Bradford Protein Assay Kit (Bio-Rad, Hercules, CA, 
USA). Proteins were separated in a 12% sodium dodecyl 
sulfate-polyacrylamide gel and transferred to polyvinylidene difluoride 
membrane (Millipore, Billerica, MA, USA). After blocking the membrane with 
Tris-buffered saline-Tween 20 (TBS-T, 0.1% Tween 20) containing 5% nonfat 
dried milk for 1 hr at room temperature, the membrane was washed twice with 
TBS-T and incubated with primary antibody for 1 hr at room temperature or 
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overnight at 4°C. The membrane was washed three times with TBS-T for 10 
min and then incubated for 1 hr at room temperature with horseradish 
peroxidase-conjugated secondary antibodies. After extensive washing, the 
bands were detected by enhanced chemiluminescence reagent (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The band intensities were quantified 
using NIH ImageJ version 1.34e software. 
 
8. RT-PCR analysis 
8.1. Isolation of total RNA 
  Total RNA was extracted by 500 µl/ 60 ㎜ plate Tri-reagent (Sigma, St. 
Louis, MO, USA). Poured 100 µl chloroform above Tri-reagent, voltexing a 
sample about 10 seconds. Then, sample was centrifuged at 12000 g, 4 ℃ and 
15 minutes. 3 layers were appeared in the tube, transparency upper layer 
collected in new tubes. And poured 250 µl 2-propanol over the sample, again 
voltex a sample about 30 seconds. Centrifuge was accomplished about 12000 
g, 4 ℃ and 10 minutes. Left the pellet, supernatant was discarded and washed 
by 75 % ethanol (Sigma, St. Louis, MO, USA) –mixed diethylpyrocarbonate 
(DEPC; Sigma, St. Louis, MO, USA) water. Centrifugation was also operated 
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about 7500 g, 4 ℃ and 5 minutes. Dismissed the supernatant, pellet was dried 
on room temperature about 7 minutes. Finally, poured the 30 µl nuclease free 
water (NFW). The quality and quantity of the RNA was detected by 
OD260/OD280 with DU 640 spectrophotometer (Effendorf, Hambug, Germany) 
 
8.2. cDNA synthesis 
  Complementary DNA (cDNA) was synthesized with RT-&GOTM. 
Quantitative 1 µg total RNA was added to 1 µl anchored primer (dT)25V, 2 µl 
dithiothreitol (DTT) and NFW, totally 9 µl volume. To prevent secondary 
structures, incubated the mixture for 5 minutes at 70 ℃ and added 8 µl of 
RT-&GOTM mastermix. Sample was incubated the assay at 42 ℃ for 1 hour. 
At the conclusion, sample was inactivated the reverse transcriptase at 70 ℃ 
for 15 minutes. Alike isolation of total RNA, sample was detected by 
OD260/OD280 with DU 640 spectrophotometer. 
 
8.3. PCR analysis 
  Quantitative 1 µg cDNA, each 10 pmol primer (forward and backward), 0.1 
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mM dNTP mixture, 1.25 U of Taq polymerase and 10 X reaction buffer were 
mixed with NFW, lastly total volume of 25 µl. PCR condition was fix as 
fellow. A cycle of denatureing at 94 ℃ for 3 minutes follwed by number of 35 
cycles with denaturation at 94 ℃ for 30 seconds, annealing at 48 ℃ to 60 ℃ 
for 30 seconds, and elongation at 72 ℃ for 30 seconds26. Then keep up 72 ℃ 
for 10 minutes. Primers were appeared Table 1. When PCR assay have 
finished, PCR product was separated by electrophoresis in a 1.2 % agarose 
gel (Bio-Rad, Hercules, CA, USA) and Gel-Doc (Bio-Rad, Hercules, CA, 
USA) visualized after staining with ethidium bromide (EtBr; Sigma, St. Louis, 
MO, USA). 
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Table 1. PCR primers used in this study 
Gene Primer Size (bp) Temp. 
Fibronectin 5’-cct taa gcc ttc tgc tct gg-3’ 5’-cgg caa aag aaa gca gaa ct-3’  300 48 
α5 integrin 5’-ctt cgg ttc act gtt cct c-3’ 5’-tgg ctt cag ggc att t  283 43 
β1 integrin 5’-gcc agt gtc acc tgg aaa at 5’-tcg tcc att ttc tcc tgt cc 344 48 
N-cadherin 5’-gcc acc ata tga ctc cct ttt agt 5’-cag aaa act aat tcc aat ctg aaa 454 48 
α1A-adrenergic receptor 5’-gag aat tcc gag gcc tca agt ccg gcc t 5’-ttg aat tct cgg gaa aac ttg agc ag 169 59 
α1B-adrenergic receptor 5’-ctg ggg aga gtt gaa aga tgc c 5’-ccg aca gga tga cca aga tgt t 158 58 
α1D-adrenergic receptor 5’-ttg aat tcc tac aga gac cca cga ccc ag 5’-cgg aat tct taa atg tca gtc tcc cgg ag 229 58 
β1-adrenergic receptor 5’-acg ctc acc aac ctc ttc at 5’-agg ggc acg tag aag gag ac 440 53 
β2-adrenergic receptor 5’-cct cat gtc ggt tat cgt cc 5’-ggc acg tag aaa gac aca atc 519 53 
M1-muscarinic receptor 5’-ctg gtt tcc ttc gtt ctc tg 5’-gct gcc ttc ttc ttc ttg ac 641 47 
M2-muscarrinic receptor ggc aag caa gag tag aat aaa gcc aac agg ata gcc aag att 552 47 
SERCA 2a tcc atc tgc ctg tcc at gcg gtt act cca gta ttg 196 42 
LTCC tgt cac ggt tgg gta gtg aa 
ttg agg tgg aag gga ctt tg 346 49 
CD34 cac ctc aga ggc tgt tct tg 
ctg gtg acc aaa aag tcc caa caa agt 437 60 
eNOS 
tcc agt aac aca gac agt gca 
cag gaa gta agt gag agc 693 40 
VE-cadherin 
aag aca tca atg aca act tcc 
cct cca cag tca ggt tat acc 590 54 
VCAM-1 
cct aag gat cca gag att caa ttc a 
ggg taa aca tca gga gcc aac 85 58 
VEGF-R2 
aga ctt tga gca tgg aag 
cca ttc cac caa aag atg 310 51 
GAPDH acc aca gtc cat gcc atc ac 
tcc acc acc ctg ttg ctg ta 450 49 
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9. In Vitro Angiogenesis 
Analysis of capillary formation was performed using the in vitro angiogenesis 
kit (Chemicon International Inc, Temecula, CA, USA) according to the 
manufacturer’s instructions. Fifty microliters of gel matrix solution were 
applied into one well of a 96-well plate and incubated for 1 hour at 37 ℃. Cells 
were then trypsinized and 5 x 103 cells were suspended in 50 µl of the DMEM 
containing VEGF and plated onto the gel matrix and incubated for 4 hours. 
Cells were counted by eye for the formation of capillary structures. The 
percentages of formed capillaries were calculated from three independent 
experiments. 
 
10. Cell counting by trypan blue stain 
The cells were washed by phosphate-buffered saline (PBS) (Gibco BRL, Grand 
Island, NY, USA). 0.5 ml of Trypan blue solution was transferred to test tube 
and added to 0.3 ml of PBS, 0.2 ml of the cell suspension was mixed thoroughly. 
Allow to stand for 5 to 15 minutes. A small amount of trypan blue-cell 
suspension was transferred to both chambers of the hematocytometer by 
carefully touching the edge of the cover-slip with the pipette tip and allowing 
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each chamber to fill by capillary action. Chamber of the hematocytometer was 
counted all the cells and dyed cell in the 1mm center square and four 1mm 
corner squares.  
  
11. Cell cycle analysis 
For cell cycle analysis, cells were harvested with trypsin, collected by 
centrifugation at 200 g for 5 min and re-suspended in PBS. Cells were again 
collected by centrifugation, monodispersed in 0.5 mL PBS and transferred to 
tubes containing 4.5 mL of cold 70% ethanol; tubes were stored at –20 °C until 
analysis. Before analysis, ethanol-suspended cells were collected by 
centrifugation at 200 g for 5 min, rinsed with PBS and re-suspended in PBS 
containing propidium iodide (50 µg/mL) and RNase A (0.2 mg/mL). A FACS 
Calibur cytometer operated with CellQuest software (Becton Dickinson, 
Franklin Lakes NJ, USA) was used for data collection. Histogram analysis and 
calculation of G1, S and G2/M percentages was performed with ModFit LT 
(Verity Software House, Topsham, ME, USA). 
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12. Statistical analysis 
Data are expressed as means ±SE. Statistical analysis of two groups were 
estimated by Student`s t-test. And examining from more than two groups was 
done by one-way ANOVA, using bonferroni test. p <0.05 was considered 
significant. 
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III. RESULTS 
1. Isolation and characterization of phynotypic markers of MSCs 
MSCs were first isolated from the mixed culture with hematopoietic cells based 
on their preferential attachment on polystyrene surfaces and the isolated MSCs 
were further purified using bead targeting hematopoietic marker CD34, yielding 
3x106 cells by 2 weeks culture and 95% purity. The MSCs retained a 
fibroblastic morphology through repeated passages and their identity was 
confirmed by immunocytochemistry and FACS analysis. The cultured MSCs 
expressed CD71, CD90, CD105, CD106, and ICAM. They expressed neither 
the hematopoietic marker CD34, nor CD14 (Fig. 1).  
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Figure 1. Characteristics of MSCs. Most adherent MSCs are practically 
fibroblastic in morphology and some polygonal cells were contained after a 
6-week culture. Magnification, 100x. Cells were cultured from bone marrow 
after density fractionation and are shown at 10 days after plating. At 14 days, 
the MSCs were positive for CD71, CD90, CD105, CD106, and ICAM-1 and 
were negative for CD14 and CD34 by flow cytometry. 
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2. Expression profile of target cell markers in MSCs treated with various 
kinase inhibitors 
Under proper stimulation, MSCs can be induced to differentiate into 
chondrocytes, myocytes, adipocytes, osteoblasts, tenocytes, and 
hematopoietic-supporting stroma. Protein kinase is the most common protein 
family that play critical role as signal switch in many signaling pathways 
presumably including cell differentiation. Since important cellular processes 
such as differentiation is likely to be controlled by a complicated orchestration 
of many signaling pathways. To examine the effect of these kinase inhibitors on 
the differentiation of rat MSCs into various cell types, the MSCs were seeded 
and treated every 3 days with the kinase inhibitors for up to 11 days. Among the 
41 inhibitors tested, 14 showed recognizable indications of inducing various cell 
types at different degrees. To assess the effectiveness of these 14 inhibitors for 
directed target cell development, we constructed a profile matrix, where the 
rows and columns represent target cell markers and kinase inhibitors, 
respectively. Using the principal component analysis (PCA) method on the 
profile matrix, we examined the relative strength of the induction and the 
cross-relationship among them. The size of the profile matrix used in PCA was 
7 x 15 in which we obtained the coordinates of inhibitors and target cell types 
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by using the first three principal components from PCA and scaled the 
coordinates to plot them together in the map for visualization. From the 
examination of Figure 2, we found several good candidates that drive rat MSCs 
into specific cell types. 
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Figure 2. Use of protein kinase inhibitors for the differentiation of MSCs. 
(A) The relative expression level of seven target cell markers (C1–C7) in the 
presence of various kinase inhibitors are detected by sandwich ELISA, and 
normalized in the range of 0 to 1 for standardization. Kinase inhibitors used (at 
1 µM) are from Calbiochem and are distinguished by the numerals after K. The 
kinases they preferentially inhibit are in parentheses: K0, no inhibitor; K1 (AKT 
1,2),1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl)
methyl)-4-piperidinyl)-2H-benzimidazol-2-one; K2 (AKT), 
1L6-hydroxymethyl-chiroinositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glyceroc
arbonate; K4 (CaMK II), Lavendustin (5-(N-2’,5’-dihydroxybenzyl) 
aminosalicylic acid); K6 (calcium channel), HA 1077 (Fasudil, 
5-isoquinolinesulfonyl)homopiperazine, 2HCl); K8 (CaseinK I), 
D4476(4-(4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-
yl)benzamide; K12 (CDK 1,2), NU6102 
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[6-cyclohexylmethoxy-2-(4’-sulfamoylanilino)purine]; K13 (TGF-βR I kinase), 
[3-(pyridin-2-yl)-4-(4-quinonyl)]-1Hpyrazole; K17 (PKA), H-89 
[N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 2HCl]; K21 
(PKC), Go¨ 6983 
(2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)) 
maleimide; K22 (PKG-1α, β), guanosine 3’,5’-cyclic monophosphorothioate, 
β-phenyl-1, N2-etheno-8-bromo-, Rp-isomer, sodium salt; K23 (EGFR PTK), 
compound 56 (4-[(3-bromophenyl)amino]-6,7-diethoxyquinazoline); K27 
(ROCK), N- (4-pyridyl)-N’-(2,4,6-trichlorophenyl) urea; K30 (DNA-PK), 
4,5-dimethoxy-2-nitrobenzaldehyde; K35 (p38 MAPK), SB 202190 
[4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole]. The 
target cells tested for each cell type were: C1, MSC positive; C2, MSC 
negative; C3, osteocyte; C4, chondrocyte; C5, cardiomycyte; C6, hepatocyte; 
C7, endothelium. The target cell markers assayed for each cell type were: C1, 
CD105; C2, CD34; C3, osteopontin (OPN); C4, aggrecan (AGG); C5, cardiac 
troponin T (CTnT); C6, CK-18, C7: CD31. (B) The effectiveness of inhibitors 
relative to the directed target cell development was analyzed by the principal 
component analysis (PCA) method using numerical values used to generate A. 
We obtained the coordinates of inhibitors and target cell types by using the first 
three principal components (for visualization) from PCA and scaled the two sets 
of the coordinates to plot them together in the map. The three largest principal 
components of PCA analysis are represented as PC1, PC2, and PC3. The 
inhibitors are indicated by red balls and the cell types are shown as green balls. 
The balls attached to the longer vectors are more efficient differentiation 
inducers for the cell types nearest to the balls. 
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3. Effect of PKA inhibitor on the differentiation of MSCs 
3.1. Effect of H-89 on the differentiation of MSCs into chondrocyte-like 
cells 
Among them, H-89, an inhibitor of protein kinase A, was found to be 
potentially implicated in chondrogenesis of the MSCs. H-89 is a derivative of 
isoquinolinesulfonamide, N-[2-((p-bromocinnamyl)amino)ethyl]-5- 
isoquinolinesulfonamide, 2HCl (Calbiochem/EMD Biosciences). The 
compound is cell-permeable and known to be selective and a potent inhibitor of 
protein kinase A (Ki = 48 nM). Among the kinases tested, it inhibited other 
kinases only at much higher concentrations: CaM kinase II (Ki = 29.7 µM), 
casein kinase I (Ki = 38.3 µM), myosin light chain kinase (Ki = 28.3 µM), 
protein kinase C (Ki = 31.7 µM), and Rho-associated kinase (ROCK)-II (IC50 = 
270 nM). To examine the capability of H-89 in inducing chondrogenesis and 
mechanisms underlying the process, we carried out several experiments with 
cell culture assays. Alcian blue bound to sulfated glucosaminoglycans was 
extracted with 6M guanidine-HCl and analyzed by measuring the absorbance at 
650nm. Quantification of chondrogenesis by measuring an absorbance of Alcian 
blue extract indicated that H-89 enhanced chondrogenesis to over 2-fold of 
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control. MSCs treated with various concentrations of H-89 (0.1–1 µM) were 
differentiated into chondrocytes in a dose-dependent manner as judged by the 
up-regulated expression of aggrecan, a chondrocyte marker. We used H-89 at 1 
µM concentration for the rest of our studies (Fig. 3).  
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Figure 3. Effect of H-89 on the differentiation of MSCs into 
chondrocyte-like cells. (A) Chondrogenesis of MSCs in vitro was significantly 
improved in cells treated with 1 µM H-89 for 11 days. The data of Alcian blue 
staining for sulfated proteoglycan indicate the quantitation of chondrogenesis. 
(B) Aggrecan, one of the extracellular matrix genes in chondrocytes, was 
induced in MSCs treated with various concentrations of H-89 for 11 days (0.1–1 
µM). The effect of U0126, a selective inhibitor of MEK, was examined on the 
expression of aggrecan. Cotreatment with 1 µM H-89 and 10 µM U0126 did not 
lead to a change of expression level. During chondrogenesis of MSC, the 
change of expression level in aggrecan was examined by sandwich ELISA. 
(**p<0.01). 
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3.2. Effect of H-89 on the phosphorylation of ERK 
The induction of chondrogenesis by H-89 is thought to be mediated by the 
(ERK) MAP kinase signaling pathway. H-89 treatment increased the 
phosphorylation of ERK through unknown pathways. ERK was expressed at the 
same level during chondrogenesis of MSCs treated with H-89. In contrast, ERK 
phosphorylation was enhanced significantly more and more during 
chondrogenesis of MSC treated with H-89. Furthermore, the treatment with 
U0126, a selective inhibitor of MEK, was shown to block the phosphorylation 
of ERK even in the presence of H-89 and nullified the chondrogenic 
inducibility of H-89 (Fig. 4).  
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Figure 4. Effect of H-89 on the phosphorylation of ERK. Activation of ERKs 
was increased in MSCs treated with 1 µM H-89 but cotreatment with 1 µM 
H-89 and 10 µM U0126 did not lead to a change in ERK activation for 11 days.  
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3.3. Effect of H-89 on the expression of cell adhesion molecules 
The effect of H-89 on differentiation of MSCs into chondrocye-like cells was 
investigated by expression level of cell adhesion molecules and extracellular 
matrix (ECM) components. Expression of N-cadherin, which mediates cell-cell 
interaction, was highest on the first day of H-89 treatment, but decreased as 
differentiation of MSC to chondrocytes proceeded. Because the interaction of 
cell with ECM in addition to cell-cell interaction is involved in the regulation of 
chondrogensis, potential involvement of H-89 in regulation of integrin α5β1 and 
its ligand fibronectin was also examined. During chondrogenic differentiation of 
MSCs treated with H-89, the fibornectin-receptor (integrin α5β1) and 
fibronectin were down-regulated (Fig. 5). 
 
 
 
 
 
 35 
 
Figure 5. Effect of H-89 on the expression of cell adhesion molecules. 
Semiquantitative RT-PCR showed a significantly changed level of cell adhesion 
molecule during chondrogenesis, using primers to the RNAs indicated. MSCs 
were cultured for the indicated time periods in the presence of 1 µM H-89. 
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4. Effect of PKC activator on the differentiation of MSCs 
4.1. Characteristics of differentiated cardiomyocyte-like cells 
After 9 days in culture, MSCs adhered to the plastic surface and were 
spindle-shaped with one nucleus. MSCs were treated with 1 µM PMA  
according to the experimental group. Treatment with PMA was every 3 days. 
The morphological differentiation from MSCs to myogenic-like cells evolved 
gradually after PMA induction. Normal MSCs were spindle-shaped until 9 days, 
but MSCs treated with PMA changed into a stick-like or branching-out 
appearance at 9 days. To examine where MHC or cTnT-expressing cells are 
located in differentiated MSCs, immunostaining was performed. Clearly, 
cardiomyocyte-like cells (CLCs) had significant morphological changes with 
positive immunocytochemical analysis for anti-MHC or -cTnT, but normal 
MSCs showed neither significant morphological changes nor cardiac-specific 
protein expression of MHC or cTnT during the 9 day period of observation with 
the same treatment (Fig. 6). 
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Figure 6. Effect of PMA on morphology of MSCs. (A) Micrographs of MSCs 
were taken after nine days.  MSCs treated with PMA changed morphology to 
cardiomyocyte-like and fibroblast-like aggregated long-branches compared to 
their counterparts. (B) Immunocytochemistry was detected for cardiac MHC 
and cTnT in MSCs treated with PMA. Representative photos of normal MSCs 
as positive control and MSCs treated with 1 µM PMA are shown 
(Magnification: X400). Cardiac MHC or cTnT visualized by FITC is located on 
the stress fibers. 
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4.2. Myogenic differentiation of MSCs by upregulating expression of 
cardiac specific markers after PMA treatment 
After 9 days of culture with the supplement of PMA, MSCs had a myocyte-like 
morphology. To reconfirm the effect of PMA on myogenic differentiation of 
MSCs, changes of cardiac specific markers expression were analyzed with 
Sandwich ELISA. In sandwich ELISA, the expression of cardiac-specific 
markers (cardiac troponin T, myosin light chain, myosin heavy chain, NK2 
transcription factor-related, locus 5, Myocyte-specific enhancer factor 2) was 
elevated time-dependently. Expression of most of the specific markers was 
peaked around 9 days. MSCs treated with PMA express multiple sarcomeric 
proteins associated with neonatal rat ventricular cardiomyocytes (NRVCM) (Fig. 
7).  
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Figure 7. Changes of cardiac specific markers in MSCs treated with PMA. 
This change was detected by sandwich ELISA. Samples of protein were lysed 
to MSCs treated with PMA each harvest day (3, 6, and 9 days). This experiment 
was repeated three times, and each standard deviation was 0.05. 
Cardiac-specific markers (cTnT, MLC, MHC, Nkx 2.5 and MEF2) were 
elevated from two days to 9 days, especially day nine, which highly expressed 
in five markers. 
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4.3. Changes of adrenergic and muscarinic receptor mRNA after PMA 
treatment 
To begin to address whether α 1-adrenergic receptors were involved in 
modulating the function of CLCs, we first detected α 1 receptor expression. 
CLCs did not express their transcripts before PMA treatment. They expressed 
α1A, α1B, and α1D receptor mRNA after treatment by PCR level. β1- and 
β2-adrenergic receptors play a crucial role in catecholamine-induced increases 
in heart rate, conduction velocity, and contractility. To explore whether β1 and 
β2 receptors are functional, we examined their expression. CLCs expressed all 
the β1 and β2 before PMA treatment. A low level of expression of β1 and β2 was 
observed before PMA treatment, but their expression was markedly augmented 
after the treatment. To date, 5 subtypes (M1 through M5) of muscarinic 
receptors have been cloned. M1 and M2 receptor subtypes are expressed in 
murine neonatal and adult cardiomyocytes. As shown in Figure 8, a low level of 
expression of both receptors
 
was observed before PMA treatment, but their 
expression was markedly augmented after the treatment. These findings showed 
that adrenergic and muscarinic receptors are expressed when they obtain the 
cardiomyocyte phenotype (Fig. 8). 
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Figure 8. Changes of adrenergic and muscarinic receptor subtype in MSCs 
treated with PMA. Each panel shows RT-PCR products for expression of α- 
(A) and β- (B) adrenergic and muscarinic (C) receptor subtypes. Bar-type 
densitometry showed that all subtypes were more expressive than normal 
control. The mRNA expression of genes was established by DNA 
electrophoresis and visualized by EtBr. Data are presented as arbitrary units 
over controls. Values are mean±SEM. *P<0.01. 
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4.4. Effect of norepinephrine on phosphorylation of ERK in MSCs treated 
with PMA  
Through α1-adrenergic receptors in cardiac myocytes, norepinephrine (NE) 
influences the contractile properties of the heart and induces a series of changes 
characteristic of the hypertrophic phenotype. To examine whether α1-adrenergic 
receptors are expressed at the protein level and transduce hypertrophic signals, 
we stimulated MSCs treated with PMA by NE and detected phosphorylation of 
ERK. Phosphorylation of ERK was induced by NE in a time-dependent manner. 
Activation of ERK by NE was detected in both MSCs treated with PMA and 
cardiomyocytes. These aspects indicated that MSCs treated with PMA 
expressed functionally active α1-adrenergic receptors (Fig. 9). 
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Figure 9. Effect of NE on activation of ERK in MSCs treated with PMA. 
Cells at two, five, and nine days (time-dependently) after PMA treatment were 
stimulated with 1 µM norepinephrine, and western blot analysis was performed 
to detect phosphorylation of ERK1/2. When MSCs treated with PMA were 
compared with cardiomyocytes under norepinephrine stimulation, the 
phosphorylation of ERK1/2 was elevated in both. *P<0.01, **P<0.001. 
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4.5. Changes in Ca2+ handling-related protein expression with MSCs 
treated with PMA 
Cardiac myocytes are progressed in excitation-contraction coupling. Molecular 
mechanisms responsible for Ca2+-handling are closely related to SERCA 2a and 
LTCC. So PCR was enforced for the expression of SERCA 2a and LTCC. 
Neonatal cardiomyocytes were highly expressed, but even MSCs treated with 
PMA were time-dependently expressed. These findings suggest that MSCs 
treated with PMA might influence Ca2+ handling-related protein expression (Fig. 
10). 
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Figure 10. Changes of Ca2+-related proteins in MSCs treated with PMA. 
MSCs treated with PMA compared to control and NRVCM in time-dependent 
measure. Each panel shows RT-PCR products for the expression of Ca2+-related 
proteins (SERCA 2a, LTCC). Densitometric analysis was performed, and the 
ratio of RT-PCR product of SERCA 2a and LTCC to that of GAPDH is shown. 
The mRNA expression was established by DNA electrophoresis and visualized 
by EtBr. Data are presented as arbitrary units over controls. Values are 
mean±SEM. *P<0.01, **P<0.001. 
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5. Effect of GSK-3β inhibitor on the differentiation of MSCs 
5.1. Effect of GSK-3β inhibitor on the differentiation of MSCs into 
endothelial-like cells 
Stem cells were seeded and treated every 3days with GSK-3β inhibitors up to a 
16-day culture. Because related specific markers were expressed during 
differentiation of stem cells into specific cell type, expression level of such 
markers were detected by sandwitch ELISA methods. An inhibitor of GSK-3β, 
was found to be potentially implicated in endogenesis of the MSCs. The 
compound is cell-permeable and known to be selective and a potent inhibitor of 
GSK-3β. Among the kinases tested, it inhibited only GSK-3β. MSCs treated 
with various concentrations of GSK inhibitor (0.1–1 µM) were differentiated 
into endothelial-like cells in a dose-dependent manner as judged by the 
up-regulated expression of CD31, a endothelial cell marker. We used GSK 
inhibitor at 1 µM concentration for the rest of our studies (Fig. 11). 
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Figure 11. Effect of GSK-3β inhibitor on the endothlium differentiation of 
MSCs. CD31, one of specific endothelial cell markers, was induced in MSCs 
treated with various concentrations of GSK-3β inhibitor for 16 days (0.1–1 µM). 
During differentiation of MSC, the change of expression level in CD31 was 
examined by sandwich ELISA. (**p<0.01). 
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5.2. Differentiation of MSCs into endothelial-like cells 
During differentiation into endothelial-like cells by cultivating confluent MSCs 
in the presence of GSK-3β inhibitor for 16 days, cell morphology showed no 
difference compared with undifferentiated MSCs. Immunohistochemical 
staining for vWF was chosen for the basal characterization of endothelial-like 
cells. Undifferentiated MSCs showed almost no specific staining for vWF, but 
after 16 days of cultivation the overall fluorescence intensity of the 
differentiated MSCs was markedly enhanced. To further establish whether these 
MSC could differentiate in response to GSK-3β inhibitor, changes of 
endothelial specific markers was analyzed with RT-PCR. After 16 days culture 
in the presence of GSK-3β inhibitor, expression of CD34, eNOS, VE-cadherin, 
VCAM-1, and VEGF-R2 was increased as compared with normal MSC (Fig. 
12). 
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Figure 12. Changes induced by differentiation of MSC into endothelial-like 
cells. (A) Immunocytochemistry was detected for VWF in MSCs treated with 
GSK-3β inhibitor. Representative photos of normal MSCs as positive control 
and MSCs treated with 1 µM GSK-3β inhibitor are shown (Magnification: 
X400). (B) This change was detected by RT-PCR. Endothelial markers (CD34, 
eNOS, VE-cadherin, VCAM-1, and VEGF-R2) were expressed in MSCs treated 
with GSK-3β inhibitor.  
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5.3. Effect of GSK-3β inhibitor on the in vitro formation of capillary 
structures 
The ability to form capillaries in semisolid medium was tested with an in vitro 
angiogenesis kit. Undifferentiated and differentiated MSCs were trypsinized and 
seeded on top of the ECmatrix gel solution. Cells were cultivated in the 
presence of VEGF and once without VEGF. The undifferentiated MSCs showed 
very few capillaries after 4 hours and most of the cells stayed round in the 
medium. When cultivated for 4 hours in the presence of VEGF, more tube-like 
structures were visible. Undifferentiated MSCs showed a substantial formation 
of capillary structures when cultivated for 4 hours in the presence of VEGF. 
After differentiation more than 70% of MSCs form capillary structures both in 
the presence and in the absence of VEGF. The cells in capillary structures 
distinctly expressed endothelial specific vWF (Fig. 13).  
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Figure 13. Endothelial-specific functional characterization of differentiated 
MSCs. (A) Light microscopic analysis of differentiated and undifferentiated 
MSC on semisolid medium in presence and absence of VEGF. Vascular tubelike 
networks were formed by differentiated MSCs on semisolid medium after 
plating. (B) Immunocytochemical staining of the vascular networks formed on 
semisolid medium for VWF (green) and DAPI (blue). Stable lumen structures 
were observed in the vascular networks during in vitro culture.  
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5.4. Effect of GSK-3β inhibitor on change of stem cell fate 
During endothelium differentiation, GSK-3β inhibitor treatment reduced the 
proliferation of MSCs compared with non-treated cells, indicating that GSK-3β 
inhibitor might modulate the balance between differentiation and proliferation. 
Cell cycle analysis showed that GSK-3β inhibitor addition led to a decrease in 
the percentage of cells in S phase. These results taken together indicate that 
treatment of proliferating MSCs with GSK-3β inhibitor leads to depletion of 
S-phase cells and over all decreased proliferation (Fig. 14). 
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Figure 14. Changes of MSC fate by GSK-3β inhibitor. (A) For cell number 
(upper panel), MSCs were seeded in plates at 1 x 105 cells/well. GSK-3β 
inhibitor was added at the indicated concentrations. The experiment was 
performed three times. Results are shown as mean ± SD. (B) Cell cycle analysis 
of cells treated with GSK-3β inhibitor or not. Cells were stained with propidium 
iodide and analysed by means of a FACS Calibur cytometer. A representative 
set of data from one of three independent experiments is shown.  
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5.5. Mechanism of GSK-3β inhibitor-induced differentiation of MSCs 
In order to study the mechanism by which GSK-3β inhibitor may induce 
differentiation of MSCs into endothelial cells, we evaluated the 
GSK-3β/β-catenin axis. GSK-3β inhibitor treatment was associated with a 
significantly increased phosphorylation of Akt, and GSK-3β. Consequently, this 
was associated with decreased phosphorylation of β-catenin, a well-known 
downstream molecule of the Akt/GSK-3β axis. In addition, the expression level 
of β-catenin in MSCs was decreased consecutively with the extension of 
differentiation time. In controls, β-catenin was predominantly immunolocalized 
at the cell periphery. However, nuclear accumulation of β-catenin 
immunostaining was markedly increased in MSCs treated with GSK-3β 
inhibitor (Fig. 15). 
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Figure 15. Effect of GSK-3β inhibitor on intracellular signaling pathway in 
endothelium differentiation of MSCs. (A) Western blot of MSCs after 
 57 
GSK-3β inhibitor treatment. GSK-3β inhibitor treatment was associated with 
activation of Akt, increased phosphorylation (thus inactivation) of GSK-3β, and 
downregulation of phospho-β-catenin. Protein levels of β-catenin decreased 
significantly during differentiation process. (B) Confocal micrographs of MSCs 
treated with GSK-3β inhibitor. Cells were stained for β-catenin (green) after 
addition of GSK-3β inhibitor. 
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IV. DISCUSSION 
Stem cells have induced increasing interest and enthusiasm because of their 
biological properties and potential medical importance. Recognition of these 
properties will need a better understanding of the signaling pathways that 
control stem cell fate and an improved ability to manipulate stem cell 
proliferation and differentiation. Specifically, the fate of stem cells is controlled 
both by intrinsic mechanism and the niche interaction. In general, stem cells are 
classified as either embryonic or adult stem cells. Embryonic stem (ES) cells are 
derived from the inner cell mass of mammalian blastocysts and are able to 
proliferate indefinitely in vitro while maintaining an undifferentiated state and 
differentiate into any possible cell type under certain conditions. By contrast, 
adult stem cells, which reside in differentiated tissues, have less potential of 
tumorigenesis but possess restricted self-renewal capacity, and can only 
differentiate into specialized cell types of the tissue in which they reside. These 
properties of stem cells make them a good source for the treatment of a number 
of diseases as well as tissue/organ injuries, including cardiovascular disease, 
neurodegenerative disease, musculoskeletal disease, diabetes, and spinal-cord 
injuries.  
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Above all, the regeneration therapy using stem cells has to meet at least two 
prerequisites: (1) the directed differentiation of stem cell to specific cell types 
and (2) prevention of undifferentiated cells becoming cancer cells. Recently, an 
increased understanding of the molecular and developmental processes for stem 
cell fate will improve the ability to manipulate stem cells for therapeutic 
applications. It has been known that expansion and differentiation of stem cell 
fate is controlled by both intrinsic regulators and the niche, such as a specific 
configuration (monolayer or three dimensional matrix), growth factors, as well 
as genetic manipulations. However, most of these conditions have some 
difficulties such as incompletely definition, or non-specificity in regulating the 
desired cellular process. Undefined condition often results in inconsistency in 
cell culture and/or heterogeneous populations of cells which would not be 
useful for cell therapy. More efficient and selective methods to control the fate 
of stem cells to produce homogenous populations of particular cell types will be 
essential to the therapeutic use of stem cells. The application of a chemical 
approach to the field of stem cell biology facilitates control over and 
understanding of stem cell fate. 
Small molecules offer several advantages that include the ability for temporal, 
tunable and modular control of specific protein function. Small molecules are 
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powerful tools in the manipulation of stem cells and complement other currently 
utilized techniques to arrive at insights into the complex molecular mechanisms 
that modulate stem cell fate. Chemical approaches hold the distinct advantages 
of precisely controlling stem cell fate in vitro for research and therapy, probing 
for new biological mechanisms, and facilitating small molecule therapeutic 
developments for modulating stem cell function in vivo for regenerative 
medicine. 
Since such important cellular processes are likely to be controlled by a 
complicated orchestration of many signaling pathways, including many as yet 
undiscovered pathways, signal modulators, such as protein kinases, are likely to 
play important role in balancing multiple signals to induce one or both of the 
prerequisites. Protein kinases belong to one of the largest protein families in 
human genome, and they play a critical role in many signaling pathways such as 
development, differentiation, proliferation or death. Several signaling pathways 
have been known to induce or suppress the differentiation of stem cells 
including those involving mitogen-activated kinases, glycogen synthase 
kinase-3, PI3 kinase, and others 23-27.  
The screening of protein kinases inhibitors described above was based on the 
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assumption that the complex orchestration of signaling pathways is responsible 
for triggering the differentiation of MSCs, and that protein kinase members play 
key role in many of the signaling pathways (Fig. 2). To test chodrogenic 
characteristics of the MSCs treated with H-89, we carried out several 
experiments using cell culture assays. Quantification of chondrogenesis by 
measuring an absorbance of Alcian blue extract indicated that H-89 enhanced 
chondrogenesis to over 2-fold of control. MSCs treated with various 
concentration of H-89 (0.1-1 µM) were differentiated dose-dependently into 
chondrocyte-like cells and chondrogenesis of MSCs upregulated expression of 
extracellular matrix gene, aggrecan. The treatment of MSCs with 1 µM H-89 
induced maximal increase of aggrecan expression to over 2 folds of the control 
(Fig. 3).  
Previous studies showed that activation of MAPK was related to induction of 
specific gene during chondrogenesis of MSCs 28. To ask whether regulation of 
chondrogenesis was mediated by MAP kinase signaling, the effect of H-89, a 
selective inhibitor of PKA, was examined on the phosphorylation and activation 
of ERK, a downstream target of PKA. Chondrogenesis of MSCs was mediated 
by ERK activation following PKA inhibition. In addition, co-treatment with 
U0126, a selective inhibitor of MEK, and H-89 did not induce the expression of 
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aggrecan and the activation of ERK during chondrogenesis of MSCs due to the 
inhibition of MEK, an upstream signaling molecule of ERK (Fig. 4).  
Extracellular molecules known to regulate chondrogenesis exert their effects at 
the level of cell proliferation and/or precartilage condensation 29-31. Precartilage 
condensation is a process that reduces intercellular spaces and formation of 
extensive cell-cell contacts between prechondrogenic mesenchymes 32-34. The 
biochemical events leading to cell condensation are not yet understood clearly. 
However, both cell-cell and cell-ECM interactions have been considered to play 
a role in precartilage condensation. Therefore, the possibility of whether H-89, a 
PKA inhibitor, regulates chondrogenesis by modulating the expression of cell 
adhesion molecules and ECM components such as N-cadherin, integrin α5β1, 
and fibronectin was investigated. 
N-Cadherin has been known to be expressed in prechondrogenic mesenchymes 
and during cell condensation 35, 36, and blockage of its function inhibited 
precartilage condensation 37. However, it was not expressed in chondrocytes 
that were completely surrounded by cartilage-specific ECM molecules 35. 
Expression of N-cadherin, which mediates cell-cell interaction, was high in first 
day but was reduced as differentiation of MSC treated with H-89 advanced to 
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chondrocyte-like cells (Fig. 5).  
Because the interaction of cell with extracellular matrix (ECM) in addition to 
cell-cell interaction is involved in the regulation of chondrogensis, a potential of 
H-89 regulation of integrin α5β1 and its ligand fibronectin was also examined. 
During chondrogenic differentiation of MSCs treated with H-89, the 
fibronectin-receptor (integrin α5β1) and fibronectin were down-regulated (Fig. 
5). The above results are consistent with the facts that an interaction of cells 
with fibronectin via integrin α5β1 is necessary for cell condensation to occur 
and that a reduction of fibronectin and its integrin α5β1 receptor after cell 
aggregation is necessary for the progression of cartilage differentiation 34, 38, 39. 
Indeed, it has been known that enhanced expression of fibronectin exerts 
negative effects on chondrogenesis 40-42. 
Treatment MSCs with H-89 retarded the proliferation activities of MSCs during 
chondrogenesis compared with control but H-89 did not have the cytotoxicity 
effect during chondrogenesis of MSCs for 11days. Namely, H-89 might 
modulate the relationship between proliferation and differentiation (Data not 
shown). In principle, one may be able to extract information about the identities 
of other protein kinases that may also negatively regulate the differentiation of 
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MSCs if one has the inhibition profile of H-89 for all known protein kinases.  
This approach can be applied to any stem cells to find chemical molecules that 
can trigger initiation of differeniation 
Results seem to validate these assumptions. Furthermore, it is also assumed that, 
since the structure of the kinase domain of all protein kinases are very similar, 
especially among the members of the same subfamily, a given kinase inhibitor 
will inhibit multiple kinases at different levels. Thus, we posit that H-89 inhibits, 
in addition to PKA, multiple signaling pathways at different levels, and the 
orchestration of these signaling pathways triggered the differentiation. Our 
result suggests that one or more signaling pathways that can be regulated by 
PKA and other unidentified kinases negatively regulate differentiation of MSCs. 
Mesenchymal stem cells (MSCs) have the potential for myocardial regeneration 
due to their self-renewal and myocardiogenic differentiation. Previously, 
researchers studying 5’-azacytidine reported that MSCs were used to 
differentiate into myocytes 43. This led to believe that MSCs are 
multi-differential cell types, and differentiation is possible without the 
genotoxic effects of 5’-azacytidine 43-45. Despite these promising results, the 
molecular mechanisms underlying myogenic differentiation from MSCs remain 
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poorly understood. The major finding of this study is a new molecular 
biological method of inducing differentiation of MSCs into cardiomyocyte-like 
cells by PMA, a protein kinase C activator, treatment.  
Protein kinases belong to one of the largest protein families in human genome, 
and they play a critical role in many signaling pathways such as development, 
differentiation, proliferation or death. The PKC family of calcium or 
lipid-activated serine-threonine kinases is regulated downstream of nearly all 
membrane-associated signal transduction pathways. About 12 different 
isozymes comprise the PKC family. The conventional PKC isozymes (PKC-α, 
-βⅠ, -βⅡ and -γ) are calcium and lipid-activated, whereas other isozymes are 
calcium independent but activated by distinct lipids (PKC-ε, -θ, -η, -δ, -ξ, -ι, -ν 
and -µ). PKC is influenced by calcium or diacylglycerol (DAG): their 
isoenzymes play a critical role in cardiomyocyte hypertrophy. Especially, 
PKC-α is reportedly capable of inducing a hypertrophic response characterized 
by enhanced sarcomeric organization and increased atrial natriuretic factor 
(ANF) expression 46, 47. Recent study demonstrated that protein kinase C (PKC) 
have the critical role of the cardiac differentiation of embryonic stem cells 48, 49. 
In addition, above data for the effect of various kinase inhibitors on 
differentiation of MSCs showed treatment of MSCs with a protein kinase C 
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inhibitor suppressed the expression of cardiomyocetic marker gene, indicating 
that activation of protein kinase C might be critical to differentiating MSCs into 
cardiomyocytes. Therefore, we hypothesized that MSCs might differentiate into 
cardiomyocyte-like cells (CLCs) after PMA treatment. 
To determine whether MSCs treated with PMA have a heart-like cell phenotype, 
we performed cardiac-specific marker-related sandwich ELISA. The highest 
expression time of all markers (cTnT, MHC, MLC, Nkx 2.5 and MEF-2) was 
nine days (Fig. 7). Moreover, the cell resembled a cardiac myocyte in 
morphology by nine days (Fig. 6). Especially, MHC and cTnT expression was 
monitored by immunocytochemistry and was found in the cytoplasm of the cells 
induced with PMA. Compared to normal MSCs, differentiated MSCs had a 
higher expression of MHC and cTnT (Fig. 6). 
To confirm whether differentiated MSCs became CLCs through a molecular 
biological approach, neurohumoral factor was used to distinguish their 
expression levels. Neurohumoral factors control heart rate, myocardial 
contractility, and cardiac hypertrophy. The most powerful system controlling 
cardiac function is the autonomous nervous system, including the sympathetic 
and parasympathetic nerves acting through adrenergic and muscarinic receptors. 
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The adrenergic receptors are divided into α-adrenergic and β-adrenergic 
receptor subtypes, and muscarinic receptors have five subtypes, M1 through M5 
50
. We explored α1A, α1B, α1D, β1, and β2-adrenergic receptors and M1 and M2 
muscarinic receptors. The characteristics of receptors include the following: 
critical implications in modulating cardiac function, α1A-, α1B-, α1D-, 
catecholamine-induced increases in heart rate, conduction velocity and 
contractility, β1- and β2-adrenergic receptors, expression in murine neonatal and 
adult cardiomyocytes, and M1 and M2 muscarinic receptors 51-54 (Fig. 8). 
Surprisingly, when MSCs treated with PMA in nine days were compared with 
normal MSCs, differentiated MSCs had a higher expression of these receptors. 
PKC is concerned about hypertrophy-related signaling. Other researchers 
showed the translocation of PKC-α in response to the α1-adrenergic and 
Gαq-coupled receptor agonist phenylephrine 55. Likewise, norepinephrine (NE) 
influences the contractile properties of the heart and induces a series of changes 
characteristic of the hypertrophic phenotype through α1-adrenergic receptors in 
cardiac myocytes 56. If MSCs differentiated into CLCs, α1-adrenergic receptors 
are expressed at the protein level and transduce hypertrophic signals. Because 
of this, the change of ERK1/2 phosphorylation was detected. When 
differentiated MSCs were treated with NE, their activation of ERK1/2 increased 
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in a time-dependent manner (Fig. 9).  
Cardiomyocytes are linked by excitation-contraction coupling, which operates 
by Ca2+ influx. LTCC and SERCA 2a are especially meaningful factors in this 
process. The mRNA of SERCA 2a is also a myocardial marker similar to the 
heart muscle-specific marker gene, cTnT 57, 58. Moreover, a 1000-fold 
Ca2+-gradient is maintained across the cardiac sarcoplasmic reticulum 
membrane by these factors, and LTCC is physiologically important in many 
excitable cells but particularly important in the heart because Ca2+ entry through 
these channels not only contributes to impulse generation and conduction but 
also serves as a second messenger to modulate regulatory protein kinases and 
the activation of contractile proteins. Thus, their expression level was analyzed. 
As seen in Fig. 10, even though NRVCMs had a slightly higher expression level, 
the MSCs’ expression level increased in a time-dependent manner. 
Finally, the prevailing evidence suggests that MSCs might differentiate into 
cardiomyocyte-like cells via PKC activation. This simple new model for 
differentiated MSCs may help clarify the cascade of transcriptional activation 
that regulates differentiation into CLCs. 
Activation of PKC is considered to be the key point in the myogenic 
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differentiation of MSCs because protein kinases play a critical role in many 
intracellular signaling pathways and differentiation of embryonic stem cell. 
Treatment of MSCs with PMA induced cardiac-specific marker expression, and 
displayed different morphological patterns, a high expression of neurohumoral 
factor and Ca2+-related protein, and a time-dependent hypertrophic expression 
compared with normal MSCs. In conclusion, PMA, a PKC activator, might 
induce the myogenic differentiation of MSCs.  
The relative ease of isolating MSCs from bone marrow and the great plasticity 
of the cells make them ideal tools for an autologous or allogeneic cell therapy 59, 
60
. The use of autologous vascular endothelial progenitor cells seems attractive 
for the development of engineered vessels as well as for the vascularization of 
engineered tissues, and may also be useful to augment vessel growth in ischemic 
tissue 61, 62.  
In previous studies, serial analysis of gene expression (SAGE) revealed that 
single cell-derived colonies of MSCs expressed mRNAs of multiple cell 
lineages, including characteristic epithelial and endothelial molecules like 
Epican and Keratins 8 and 10 63. These data suggest that the in vitro 
differentiation potential of MSCs is not restricted to mesodermal lineages but 
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also transdifferentiation of MSCs into other lineages like endothelial could be 
realized in vitro and in vivo.  
The formation of endothelial tissue (vasculogenesis) is a process in which the 
embryo angioblasts are differentiated from mesodermal cells and organized to 
form a primitive vascular network 64. Angiogenesis, the formation of new blood 
vessels by sprouting from pre-existing vessels, occurs in many situations such as 
embryonic development and pathological conditions like tissue ischemia. 
Although the molecular mechanisms responsible for vasculogenesis and 
angiogenesis are currently not fully understood, the pivotal role of glycogen 
synthase kinase-3β (GSK-3β) for both processes is evident.  
GSK-3β is a serine/threonine kinase that is under the control of Wnt 65, 66 
signaling pathways. Recently, it has been shown that a pharmacological 
inhibitor of GSK-3β promotes the self-renewal of embryonic stem cells in vitro 
67
. GSK-3β controls several downstream transcription factors that are crucial in 
cell survival and function including β-catenin 68, heat shock factor-1 69, 
cAMP-response element-binding protein 70, AP-1 71, Myc 72, NFAT 73, 
CCAAT/enhancer-binding protein α 74, and cyclin D1 75. GSK-3β has also been 
shown to be involved in the regulation of angiogenesis through its ability to 
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modulate vascular endothelial cell migration and survival 76. Previous studies 
indicated a pharmacological inhibitor of GSK-3β lead to the differentiation of 
endothelial progenitor cells and monocytes into endothelial cells 77, 78. Hence, 
our study shows that GSK-3β is one of factors for the in vitro differentiation of 
mesenchymal stem cells into endothelial cells in vitro.  
Several populations of bone marrow-derived cells have the potential to 
differentiate into endothelial-like cells. CD133+ HSCs cultivated at high cellular 
density and in the presence of endothelial growth factors like VEGF were 
shown to acquire endothelial features 79, 80, and CD34+ HSCs isolated from 
peripheral blood can differentiate into endothelial cells in vitro 81 and contribute 
to vascularization in animal models 82. Regardless of this fact, the major 
advantage of MSCs is the vast number of cells that can be achieved from one 
bone marrow aspirate. MSCs were shown to be genetically stable over many 
passages 83. 
The treatment of MSCs with GSK-3β inhibitor triggered endothelium 
differentiation in a dose-dependent (0.1–1 µM) manner as judged by the 
up-regulated expression of CD31, a endothelial cell marker (Fig. 11). In our 
differentiation system MSCs acquire major characteristics of mature 
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endothelial-like expression of CD 34, eNOS, VCAM-1, VEGF-R2, 
VE-cadherin, and vWF (Fig. 12).  
After differentiation, the formation of capillary-like structures in semisolid 
medium was markedly enhanced when cells were cultivated without VEGF. 
Recent studies have shown that murine stroma cells can also be differentiated 
into vasculature-forming cells under hypoxic conditions or genetic modification 
84, 85
. It was also found that MSCs form tube-like structures when cultivated in 
semisolid medium; the presence of VEGF markedly enhanced this behavior. 
Interestingly, the numbers of capillary-like cells in this assay were strongly 
enhanced in predifferentiated MSCs (Fig. 13). Hypoxia upregulates several 
genes involved in angiogenesis like basic fibroblast growth factor, VEGF, the 
VEGF receptors KDR and FLT-1, and components of the plasminogen system 86. 
Differentiation of MSCs with GSK-3β inhibitor also upregulates the expression 
of the VEGF receptors KDR and FLT-1, which play a major role in 
angiogenesis in vivo and contribute together with matrix-metalloproteases to the 
formation of capillary-like structures in vitro.  
In the figure 14, a pharmacological inhibitor of GSK-3β retarded the 
proliferation activities of MSCs during endothelium differentiation of MSCs. 
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Namely, GSK-3β might modulate the balance between proliferation and 
differentiation. In cell cycle analysis, a decrease in the percentage of cells in S 
phase ascertained differentiation induction of GSK-3β. In addition, GSK-3β has 
been known as a regulator of angiogenesis through modulation of downstream 
transcription factors including β-catenin and so on. Our present study showed 
that the treatment of GSK-3β inhibitor is associated with a significant increase 
in GSK-3β phosphorylation, resulting in its inactivation, and thus 
downregulation of phospho-β-catenin and nuclear accumulation of β-catenin 
(Fig. 15). 
Observations described above, the enhanced differentiation of MSCs to 
chondrocytes, cardiomyocytes, and endothelial cells, support the notion that, 
although cell differentiation may be the result of a complex orchestration of 
many signals from multiple signaling pathways, even a single chemical reagent, 
a kinase inhibitor in this case, can alter the relative balance of many signals 
enough to enhance differentiation of stem cells to particular cell types. They 
also suggest that the process may be optimized by a ‘‘mixture’’ of various 
multiple kinase inhibitors.  
Because these compounds may interact with ‘‘off-target’’ kinases as well as 
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other unknown proteins, our observation should be considered as a practical 
approach for finding chemical reagents for inducing stem cell differentiation to 
a specific cell type even when most of the signaling pathways are unknown. 
Thus, the approach described or some variation of it may be applied to other 
stem cells, including human stem cells, to find chemical molecules that can 
trigger initiation, inhibition, or even reversion of the differentiation process of 
stem cells or progenitor cells. 
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V. CONCLUSION 
Although cell differentiation may be the result of a complex orchestration of 
many signals from multiple signaling pathways, even a single chemical reagent, 
a kinase inhibitor/activator in this case, can alter the relative balance of many 
signals enough to enhance differentiation of stem cells to particular cell types. 
They also suggest that the process may be optimized by a ‘‘mixture’’ of various 
multiple kinase inhibitors/activators. Because these compounds may interact 
with ‘‘off-target’’ kinases as well as other unknown proteins, the observation 
should be considered as a practical approach for finding chemical reagents for 
inducing stem cell differentiation to a specific cell type even when most of the 
signaling pathways are unknown. The approach described or some variation of 
it may be applied to other stem cells, including human stem cells, to find 
chemical molecules that can trigger initiation, inhibition, or even reversion of 
the differentiation process of stem cells or progenitor cells. 
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Abstract (in Korean) 
 
단백질 키나아제 신호 체계 조절에 의한 골수 유래 
간엽줄기세포의 특이적 분화 유도 
 
< 지도교수 장 양 수 > 
 
연세대학교 대학원 의과학과 
장 우 철 
 
 
현재까지 알려진 많은 신호 기전을 조절하는 단백질들 중 하나인 단백질 
키나아제는 줄기세포의 분화 조절에서 중요한 역할을 할 수 있으며 이는 
세포의 운명과 같은 중요한 생물학적 과정이 다양한 신호기전의 섬세한 
조합에 의해 결정되어지기 때문이다. 게다가, 단백질 키나아제의 활성을 
조절하는 세포 투과성 저분자화합물은 특정 단백질의 기능을 시간적, 양적 
그리고 모듈단위로 조절할 수 있는 장점을 가지고 있다. 따라서 본 
연구에서는 간엽줄기세포의 분화를 체계적으로 조절하는 화학물질과 
기전에 대해 알아보고자 하였으며 다양한 신호기전의 조합을 조절할 수 
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있는 주요한 단백질 키나아제 군의 억제제 스크리닝을 통해 몇몇 단백질 
키나아제가 간엽줄기세포의 분화에 상당한 영향을 미침을 발견하였다. 
우선, PKA 억제제인 H-89를 줄기세포에 처리한 결과, 생체외에서 
연골세포로의 분화과정이 증진되었다. H-89를 처리한 뒤 연골세포로의 
분화 정도를 측정하는 alcian blue 염색 정도가 증가하였다. 다양한 농도 
(0.1-1 μM)의 H-89를 간엽줄기세포에 처리할 경우, 연골세포의 세포외 
기질에 존재하는 단백질들 중 하나인 aggrecan의 발현이 유도되었다. 
간엽줄기세포가 연골세포로 분화되는 과정에서 ERK의 활성은 증가하였으나 
H-89과 U0126을 동시에 처리할 경우 ERK의 활성은 증가하지 않았다. 
연골세포로의 분화과정에서 세포 생착과 관련된 분자의 발현에서 상당한 
변화가 유발됨을 RT-PCR을 통해 확인하였다. PKC 활성제인 phorbol 
myristate acetate (PMA)의 처리는 간엽줄기세포에서 심근세포의 특이적 
표현인자 (cardiac troponin T, myosin light chain, myosin heavy chain, 
NK2 transcription factor-related, locus 5, 그리고 Myocyte-specific 
enhancer factor 2)의 발현을 유발시켰다. 분화 유도된 심근세포는 
기능인자인 adrenergic과 muscarinic 수용체가 발현되고 norepinephrine을 
처리하면 발현된 α1-adrenergic 수용체를 통해 ERK의 인산화가 
유발되었다. 칼슘 관련 인자(sarcoplasmic reticulum Ca2+-ATPase 
그리고 L-type Ca2+ channel)의 mRNA 발현 수준은 분화 유도된 
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간엽줄기세포와 심근세포에서 유사성을 보였다. GSK-3β inhibitor 
처리에 의해 내피유사세포로의 분화가 유도되었으며 분화 유도된 세포는 
내피세포의 특이적 표현인자(CD31, CD34, eNOS, VE-cadherin, VCAM-1, 
그리고 VEGF-R2) 발현의 상당히 증가하였으며, 또 모세혈관과 유사한 
구조의 형성과 같은 기능적 특성을 보였다. 간엽줄기세포에 GSK-3β 
inhibitor를 처리하면 세포주기 중 S기가 감소하고 전반적으로 생육이 
저하되었다. 신호 물질의 분석을 통해 GSK-3β inhibitor 처리에 의한 
내피세포로의 분화에는 GSK-3β/β-catenin 하위신호기전이 관련되어 
있음을 알 수 있었다. 본 연구는 단백질 키나아제의 조절이 
간엽줄기세포의 체계적인 분화 조절 방법이 될 수 있으며 이 체계는 
간엽줄기세포에 대한 학문적 이해와 새로운 재생의학의 발달에 기여할 
것으로 기대된다.      
------------------------------------------------------------------------------------------------------------------ 
핵심되는 말: 간엽줄기세포, 분화, 단백질 키나아제, 신호기전 
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